Long-term denosumab increased bone mineral density in postmenopausal women.
Age significantly affected the association between hot flash status and flow-mediated dilation, particularly in younger women.
The fewer menstrual cycles women had over a lifetime placed them at greater risk for incident heart failure.
Research results indicate that more randomized clinical trials are needed to examine the relationship between hearing loss and oral hormone replacement therapy.
After 24 months, bone mineral density was statistically different from baseline.
Serum samples, spirometry, and questionnaire data were collected from nearly 1500 women to determine if menopausal status affected lung function.
Findings in postmenopausal women with T2DM; correlations prominent in those with higher 25(OH)D
Researchers examined body mass index differences in current, past, and never users of menopausal hormone therapy.
HRT in postmenopausal women was linked to lower CAC scores and a lower risk of long-term, all-cause mortality.
Severe anxiety was independently associated with poor quality of life in postmenopausal patients.
Endocrinology Advisor Articles
- Maternal Deaths in the United States: Sounding a Call to Action
- Semaglutide Improved Beta-Cell Function and Glycemic Control in Type 2 Diabetes
- Blood Glucose Self-Monitoring in Type 2 Diabetes Does Not Benefit Glycemic Control
- Major Cardiovascular Event Incidence in T2D: Degludec vs Glargine
- The Handoff: Your Week in Endocrinology News - 6/23/17
- Reduced Cardiovascular Events in Type 2 Diabetes Treated With Dapagliflozin
- Canagliflozin Reduces Cardiovascular Stress In Older Patients With Type 2 Diabetes
- Diabetic Retinopathy Caused by Sleep Apnea in T2D
- Transition-of-Care Algorithm Performs Well in Surgery Patients With Type 2 Diabetes
- GLP-1 Analog Counteracts Antipsychotic-Induced Glucose Intolerance, Weight Gain